6,560% Dividend: Pharma Stock in Focus After Announcing Q4 Results and Dividend

Synopsis: Pharma stock in focus after Q4 results and a 6,560 percent dividend announcement, supported by steady revenue and profit growth along with strong FY26 performance. 

The share of this company, which is a major, publicly listed subsidiary of Abbott Laboratories, focused on providing high-quality branded generic pharmaceuticals, nutritionals, diagnostics, and vascular devices, gained focus after posting Q4 results.

With a market capitalization of Rs 57,534 crore, Abbott India Ltd’s share price on Tuesday hit a day low of Rs 26,861.55 per share, down by 3.29 percent from its previous day’s close of Rs 27,776.95 per share. The share of this company gave a return of 67 percent over the last five years.

Results Overview

QoQ View: The revenue from operations saw a slight decline of 0.8 percent to Rs 1,710 crore in Q4 FY26 from Rs 1,724 crore in Q3 FY26 (Dec 2025). However, EBIDT grew by 3.9 percent to Rs 481 crore from Rs 463 crore in the previous quarter. This was supported by a 5 percent increase in net profit to Rs 395 crore from Rs 376 crore, which led to an EPS improvement of 5 percent to Rs 185.86 per share from Rs 176.93 in Q3 FY26. 

YoY View: The revenue from operations grew by 7 percent to Rs 1,710 crore in Q4 FY26 (Mar 2026) from Rs 1,605 crore in Q4 FY25 (Mar 2025), and EBIDT grew by 12 percent to Rs 481 crore in Q4 FY26 from Rs 429 crore in Q4 FY25. Accompanied by a net profit growth of 8 percent to Rs 395 crore in Q4 FY26 from Rs 367 crore in Q4 FY25, resulting in an EPS growth of 8 percent to Rs 185.86 per share in Q4 FY26.

Fiscal year comparison: Revenue from operations stood at Rs 6,929 crore in FY26 versus Rs 6,409 crore in FY25, a rise of 8.1 percent. Operating margin improved to 27 percent in FY26 from 26 percent in FY25. Profit before tax was Rs 2,079 crore in FY26 compared to Rs 1,887 crore in FY25, up 10.2 percent, while net profit increased to Rs 1,552 crore in FY26 from Rs 1,414 crore in FY25, up 9.8 percent.  

Dividend: The Board of Directors has recommended a final dividend of Rs 525 per equity share and a special dividend of Rs 131 per equity share of face value Rs 10 each for FY26, subject to shareholder approval. This translates to a total dividend of Rs 656 per share, or 6,560 percent. The record date is fixed as July 24, 2026, and payment will be made on or after August 18, 2026, if approved at the AGM.

About the Company

Abbott India Limited is a major, publicly listed subsidiary of Abbott Laboratories, focused on providing high-quality branded generic pharmaceuticals, nutritionals, diagnostics, and vascular devices. Headquartered in Mumbai, it is one of India’s fastest-growing healthcare companies, leading in therapeutic areas like women’s health, gastroenterology, and metabolic disorders. 

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post 6,560% Dividend: Pharma Stock in Focus After Announcing Q4 Results and Dividend appeared first on Trade Brains.